Dr. Eytan Stein on Multiple Targets in Acute Myeloid Leukemia
Eytan Stein, MD, discusses targeting multiple mutations in patients with acute myeloid leukemia (AML).
Eytan Stein, MD, hematologist/oncologist, Memorial Sloan Kettering Cancer Center, discusses targeting multiple mutations in patients with acute myeloid leukemia (AML).
Stein says all patients with AML have a multitude of mutations that are causing their disease, and that targeting single mutations such as FLK3 and IDH may not be enough to make an impact. He adds that combining agents that, for example, target both of those mutations could very well be the future of the treatment paradigm.
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
